Chung O, Yao S, Yang F, Wang L, Cerda-Smith C, Hutchinson H
bioRxiv. 2025; .
PMID: 40027615
PMC: 11870461.
DOI: 10.1101/2025.02.18.638901.
Dehkordi S, Wong I, Ni J, Luebeck J, Zhu K, Prasad G
Nat Commun. 2025; 16(1):1497.
PMID: 39929823
PMC: 11811125.
DOI: 10.1038/s41467-025-56670-8.
Yang Q, Xie Y, Qiao K, Lim J, Wu S
Cell Res. 2025; 35(1):11-22.
PMID: 39748050
PMC: 11701097.
DOI: 10.1038/s41422-024-01054-8.
Wang Z, Yu J, Zhu W, Hong X, Xu Z, Mao S
Mol Cancer. 2024; 23(1):276.
PMID: 39707444
PMC: 11660679.
DOI: 10.1186/s12943-024-02187-5.
Simovic-Lorenz M, Ernst A
Nat Rev Cancer. 2024; 25(2):79-92.
PMID: 39548283
DOI: 10.1038/s41568-024-00769-5.
Bioinformatics advances in eccDNA identification and analysis.
Li F, Ming W, Lu W, Wang Y, Dong X, Bai Y
Oncogene. 2024; 43(41):3021-3036.
PMID: 39209966
DOI: 10.1038/s41388-024-03138-6.
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance.
Engel J, Zhang X, Wu M, Wang Y, Espejo Valle-Inclan J, Hu Q
Cell. 2024; 187(21):6055-6070.e22.
PMID: 39181133
PMC: 11490392.
DOI: 10.1016/j.cell.2024.08.001.
Characterization, biogenesis model, and current bioinformatics of human extrachromosomal circular DNA.
Zhou L, Tang W, Ye B, Zou L
Front Genet. 2024; 15:1385150.
PMID: 38746056
PMC: 11092383.
DOI: 10.3389/fgene.2024.1385150.
Imaging extrachromosomal DNA (ecDNA) in cancer.
Purshouse K, Pollard S, Bickmore W
Histochem Cell Biol. 2024; 162(1-2):53-64.
PMID: 38625562
PMC: 7616135.
DOI: 10.1007/s00418-024-02280-2.
RNA Polymerase II hypertranscription at histone genes in cancer FFPE samples.
Henikoff S, Zheng Y, Paranal R, Xu Y, Greene J, Henikoff J
bioRxiv. 2024; .
PMID: 38559075
PMC: 10979862.
DOI: 10.1101/2024.02.28.582647.
Extrachromosomal DNA in cancer.
Yan X, Mischel P, Chang H
Nat Rev Cancer. 2024; 24(4):261-273.
PMID: 38409389
DOI: 10.1038/s41568-024-00669-8.
Breakage fusion bridge cycles drive high oncogene copy number, but not intratumoral genetic heterogeneity or rapid cancer genome change.
Dehkordi S, Wong I, Ni J, Luebeck J, Zhu K, Prasad G
bioRxiv. 2024; .
PMID: 38168210
PMC: 10760206.
DOI: 10.1101/2023.12.12.571349.
Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma.
Chapman O, Luebeck J, Sridhar S, Wong I, Dixit D, Wang S
Nat Genet. 2023; 55(12):2189-2199.
PMID: 37945900
PMC: 10703696.
DOI: 10.1038/s41588-023-01551-3.
Scrambling the genome in cancer: causes and consequences of complex chromosome rearrangements.
Krupina K, Goginashvili A, Cleveland D
Nat Rev Genet. 2023; 25(3):196-210.
PMID: 37938738
PMC: 10922386.
DOI: 10.1038/s41576-023-00663-0.
Extrachromosomal DNA (ecDNA) in cancer: mechanisms, functions, and clinical implications.
Dong Y, He Q, Chen X, Yang F, He L, Zheng Y
Front Oncol. 2023; 13:1194405.
PMID: 37448518
PMC: 10338009.
DOI: 10.3389/fonc.2023.1194405.
Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.
Wang D, Hao S, He H, Zhang J, You G, Wu X
J Cell Mol Med. 2023; 27(16):2424-2436.
PMID: 37386793
PMC: 10424286.
DOI: 10.1111/jcmm.17828.
Demystifying extrachromosomal DNA circles: Categories, biogenesis, and cancer therapeutics.
Wu M, Rai K
Comput Struct Biotechnol J. 2022; 20:6011-6022.
PMID: 36382182
PMC: 9647416.
DOI: 10.1016/j.csbj.2022.10.033.
Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance.
Pecorino L, Verhaak R, Henssen A, Mischel P
Biochem Soc Trans. 2022; 50(6):1911-1920.
PMID: 36355400
PMC: 9788557.
DOI: 10.1042/BST20221045.
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases.
Yang L, Jia R, Ge T, Ge S, Zhuang A, Chai P
Signal Transduct Target Ther. 2022; 7(1):342.
PMID: 36184613
PMC: 9527254.
DOI: 10.1038/s41392-022-01176-8.
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges.
Noorani I, Mischel P, Swanton C
Nat Rev Clin Oncol. 2022; 19(11):733-743.
PMID: 36131011
DOI: 10.1038/s41571-022-00679-1.